PutmanMS, NorrisAW, HullRL, et al.Cystic fibrosis–related diabetes workshop: Research priorities spanning disease pathophysiology, diagnosis, and outcomes. Diabetes Care, 2023; 46(6):1112–1123.
2.
EdlundA, EsguerraJL, WendtA, et al.CFTR and Anoctamin 1 (ANO1) contribute to cAMP amplified exocytosis and insulin secretion in human and murine pancreatic beta-cells. BMC Med, 2014; 12:87.
3.
SheikhS, GudipatyL, De LeonDD, et al.Reduced β-cell secretory capacity in pancreatic-insufficient, but not pancreatic-sufficient, cystic fibrosis despite normal glucose tolerance. Diabetes, 2017; 66(1):134–144.
4.
NyirjesySC, PeleckisAJ, EielJN, et al.Effects of GLP-1 and GIP on islet function in glucose-intolerant, pancreatic-insufficient cystic fibrosis. Diabetes, 2022; 71(10):2153–2165.
5.
GnanapragasamH, MustafaN, BierbrauerM, et al.Semaglutide in cystic fibrosis-related diabetes. The Journal of Clinical Endocrinology & Metabolism, 2020; 105(7):2341–2344.
